(Q33938906)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

CCK-B antagonists in the control of anxiety and gastric acid secretion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

M S Chambers

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

S R Fletcher

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

Progress in medicinal chemistry

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

45-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Neuronal cholecystokinin: one or multiple transmitters?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Two brain cholecystokinin receptors: implications for behavioral actions.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Neuropharmacology of anxiety: perspectives and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

CCK in animal and human research on anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin and morphine analgesia: variations on a theme

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin receptor binding in morphine analgesia: tolerance, withdrawal and abstinence.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin antagonists--a toxicologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Gastrin is a major mediator of the gastric phase of acid secretion in dogs: proof by monoclonal antibody neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Effect of gastrin receptor antagonists on gastric acid secretion and gastrin and somatostatin release in the rat stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Synthesis and evaluation of 1,5-benzodiazepines with bridged cycloalkyl substituents at the N-1 position as potent and selective CCK-B Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Molecular and pharmacological characterization of the human CCKB receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

On the biologically active structures of cholecystokinin, little gastrin, and enkephalin in the gastrointestinal system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Evaluation of biologic gastrin activity of compound CI-988 in the isolated, vascularly perfused rat stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Quinazolinone cholecystokinin-B receptor ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

CCK in anxiety and cognitive processes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

The anxieties of drug discovery and development. CCK-B receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970057-2

7 January 2021

10.1016/S0079-6468(08)70057-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10845247%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference